AI-Driven Discovery Will Advance Biologic Drug Development

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

05 May 25

AnalystConsensusTarget's Fair Value

US$4.00

50.8% undervalued

04 Sep

US$1.97

233.9%

11.3%

233.9%

11.3%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$450.8% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$4

50.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

18.55%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.31%

Calculation

CA$13.13m

Earnings '28

52.75x

PE Ratio '28

CA$692.39m

Market Cap '28

CA$692.39m

Market Cap '28

101.40m

No. shares '28

CA$6.83

Share Price '28

CA$6.83 Share Price '28

Discounted to 2025 @ 7.35% p.a.

CA$5.52

Fair Value '25

CA$5.52 Fair Value '25

Converted to USD @ 0.7247 CAD/USD Exchange Rate

US$4.00

Fair Value '25